David J. Ecker

Dr. Ecker is CEO of Janus-I Science Inc. and former co-founder of Isis Pharmaceuticals and former Founder of the Ibis Biosciences where he was Chief Scientific Officer. Dr. Ecker was instrumental in the development of the Ibis T5000 (formerly TIGER) program for infection control, infectious disease diagnostics, biological weapons defense sponsored by DARPA, CDC, NIAID, FBI and DHS. Prior to Isis, Dr. Ecker was Assistant Director, Department of Molecular Genetics at SmithKline and French Laboratories (SK&F). While at SK&F, he focused on applications of molecular biology to drug discovery. Dr. Ecker contributed to a number of SK&F therapeutic programs including cancer, arthritis/inflammation, antiviral, and antifungal. He also designed and supervised the SK&F oligonucleotide synthesis facility. Dr. Ecker has published extensively in fields that include biodefense technology development, chemistry, DNA synthesis, gene construction and expression, protein structure and function, enzymology, and gene regulation. He has authored more than 100 scientific publications and issued more than 50 U.S. patents. Dr. Ecker received his Ph.D. in chemistry and biochemistry from Utah State University and was an American Cancer Society Fellow in chemistry at the University of California, Berkeley. He brings considerable expertise to Lumiphore including patent management, business development, strategic direction and the management of corporate and government partnerships from his over 25 years of experience in the pharmaceutical/biotechnology.